NEWSLETTER

Fields marked with "*" are required to fulfill.
  • Genome editing enters a new phase

    01/08/2018
    Posted by:

    Merogenomics 


    The world of genome editing is heating up. Since its invention in 2012 of the targeted Cas9 gene editing system, the procedure has garnered massive funding and attention, and it is no wonder, as the potential medical implications are obvious. Quietly in the background, human embryo experiments are already occurring, setting the stage for what might be expected in the near future.


  • Epizyme company in search of the first ever epigenetic cancer therapy

    28/06/2018
    Posted by:

    Merogenomics


    Tazemetostat is a drug for patients with specific genetically-defined tumors. This is how the future of both clinical trials and personalized targeted therapy is going to be defined. Well, perhaps more accurately, that future had arrived a long time ago, it is just that unfortunately not many oncologists are yet aware of or know how to apply such medications. But everything requires its time to mature, and eventually all of our oncologists will be sequencing patient cancer DNA without a second thought.


  • BabySeq, a catchy name, a catchy way to study the future

    30/09/2017
    Posted by:

    Merogenomics


    There are massive studies underway in the US right now that are checking into the idea of what societal health benefits can be derived by screening babies upon birth with the sequencing of their genomes. This is a very laborious undertaking, combining the research efforts of many clinical institutions, as well as many scientists and physicians, and is scrutinized throughout the process from every angle possible. It is desirable to find out how good such sequencing would be for babies to be healthier, how accurate the process could be, how dangerous, how costly, and what impact can be expected. It will require many years of examination to bring all of the necessary data required to guide future health policies and standards.


  • Synthesising humans, a modern topic of debate?

    27/07/2017
    Posted by:

    Merogenomics


    One genome-related newstory that has stirred the public lately was last year’s announcement of a project to synthetically build a human genome. What do I mean by that? To build an entire human genome, the DNA code that makes each individual unique, with a machine base by base, chromosome by chromosome. You can imagine such information elicited quite a few gasps among the bewildered public.


  • How to tell if your genes could be acted on to help

    13/05/2017
    Posted by:

    Merogenomics


    "Actionable" genes are the genes that if mutated can lead to serious health complications, but where something can actually be done about it for a patient if discovered. So being able to determine what constitutes a gene with beneficial treatment or intervention to take place is definitely important! This is particularly timely work in light of emerging evidence of genetic testing leading to bad decisions with no benefit to patients.


  • Pregnancies just got new test to study fetus

    24/04/2017
    Posted by:

    Merogenomics


    What has changed, quite recently, is how pregnant women have started applying genomic technologies to assess the health risks of their babies, even prior to being born. Colloquially known as NIPT test, which stands for a non-invasive prenatal test, it is a term that is rapidly becoming familiar to pregnant women.